Pneumococcal polysaccharide vaccine efficacy and routine use of conjugate vaccines in infants: There is no need for a vaccine program in older adults at present

Johannes Trück*, Rajeka Lazarus, Ingileif Jonsdottir, Keith P. Klugman, Andrew J. Pollard

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

16 Citations (Scopus)
Original languageEnglish
Pages (from-to)1577-1579
Number of pages3
JournalClinical Infectious Diseases
Volume55
Issue number11
DOIs
Publication statusPublished - 1 Dec 2012

Bibliographical note

Funding Information:
Potential conflicts of interest. J. T. and R. L. have received financial assistance from manufacturers of pneumococcal vaccines to attend scientific meetings. A. J. P. has acted as an investigator on clinical trials of pneumococcal vaccines including those that are discussed in this letter. He does not receive any personal payments or travel expenses from vaccine manufacturers but his institution receives grants for research on pneumococcal vaccines and unrestricted educational grants for symposia and courses directed by A. J. P. I. J. has acted as principal investigator and investigator on clinical trials of experimental and currently licensed PCVs. Her institution (Landspitali, The National University Hospital of Iceland) has received research grants from a vaccine manufacturer and she has received travel grants and honoraria for lectures at scientific meetings. K. P. K. has consulted for and received speaking fees from various vaccine manufacturers, and his institution has received a research grant from a vaccine manufacturer.

Funding Information:
European Society of Paediatric Infectious Diseases fellowship award and a James Martin Fellow. A. J. P. is a Jenner Institute Investigator and James Martin Senior Fellow.

Cite this